[Management of arterial hypertension in octogenarian].

Hypertension is the most common chronic condition for which elderly people see a health provider and is increasing in prevalence as people age. The most powerful risk factor for death, cardiovascular death, and hypertension in large populations is age. In the very elderly patient the most common abnormality is elevated systolic blood pressure, which is much more predictive of stroke and heart disease death. With the exception of the Antihypertensive and Lipid Lowering to prevent Heart Attack Trial (ALLHAT), recent trials have emphasized the overriding importance of lowering blood pressure rather than the specific agent chosen to begin therapy. A metaanalysis of 7 clinical trials that enrolled 1.670 subjects > 80 years od age indicated that active antihypertensive drug therapy significantly reduce stroke by 34% and heart failure by 39% was associated with a non significant 6 increase in mortality. The Hypertension in the Very Elderly Trial (HYVET) will enrol 2.100 patients > 80 years of age and will compare 2 groups randomized to indapamide +/- perindopril versus placebo +/- placebo for incident stroke during 5 years follow-up. This study should answer lingering question about whether active antihypertensive therapy is associated with a major and significant reduction in cardiovascular morbidity and mortality in this age group as it clearly does in younger hypertensives. For frail patients, further studies are needed to assess the potential risks associated to antihypertensive therapy according to the characteristics of the geriatric patient.